Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Beule, Dieter Dr. (6) Blankenstein, Thomas Prof. Dr. (179) Bunse, Mario Dr. (3) Cakmak-Görür, Nese Dr. (1) Clauß, Julian (1) Daniel, Peter Prof. Dr. (4) Dhamodaran, Arunraj (2) Dyck, Lydia Dr. (1) Filosa, Alessandro Dr. (1) Gerhardt, Holger Prof. Dr. (1) Henssen, Anton Prof. Dr. med. (1) Höpken, Uta Elisabeth PD Dr. (2) Hübner, Norbert Prof. Dr. (1) Ivics, Zoltan Dr. (1) Izsvak, Zsuzsanna Dr. (1) Jeuthe, Sarah Dr. (1) Kammertöns, Thomas Dr. (38) Keller, Ulrich Dr. med. (1) Kieback, Elisa Dr. (3) Kühn, Ralf Dr. (1) Kunz, Severine Dr. (1) Lorenz, Felix Dr. (1) Marko, Lajos Dr. (1) Mertins, Philipp Dr. (3) Na, Il-Kang Dr. (2) Nguyen, Tam Hoai Dr. (1) Obermayer-Wasserscheid, Benedikt Dr. (1) Patone, Giannino Dr. (1) Pezzutto, Antonio Prof. Dr. (17) Poncette, Lucia (4) Popp, Oliver Dr. (3) Rahn, Hans-Peter Dr. (1) Rathjen, Fritz Prof. Dr. (1) Rehm, Armin Dr. (1) Rhein, Simone Dr. (2) Richter, Matthias (1) Rosenberger, Leonie Milena (1) Sawamiphak, Suphansa Dr. (1) Schlag, Peter M. Prof. Dr. (1) Schmitt, Clemens Prof. Dr. (1) Schütz, Anja Dr. (1) Siffrin, Volker (1) Sporbert, Anje Dr. (1) Stein, Ulrike Prof. Dr. (3) Uckert, Wolfgang Prof. Dr. (23) Walther, Wolfgang Prof. Dr. (7) Willimsky, Gerald Dr. (34) Wolf, Susanne Dr. (2) (-) Kopp, Joachim Dr. (5) (-) Leisegang, Matthias Prof. Dr. rer. nat. (10) Electron Microscopy (1) Genetik und Genomik von Herz- Kreislauferkrankungen (1) Integrative Vaskuläre Biologie (1) (-) Molekulare Immunologie und Gentherapie (15) Strukturbiologie Membran-assoziierter Prozesse (5) Translational Bioinformatics (1) 2005 (1) 2006 (1) 2010 (2) 2011 (2) 2013 (1) 2015 (3) 2016 (1) 2017 (1) 2018 (1) 2020 (1) 2022 (1) 15 Ergebnisse: Active Filter: Kopp, Joachim Dr.Leisegang, Matthias Prof. Dr. rer. nat.Molekulare Immunologie und Gentherapie Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 08. Februar 2013 / Mol Med High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination H. Pohla A. Buchner B. Stadlbauer B. Frankenberger S. Stevanovic S. Walter R. Frank T. Schwachula S. Olek J. Kopp G. Willimsky C.G. Stief A. Hofstetter A. Pezzutto T. Blankenstein R. Oberneder D.J. Schendel 01. März 2016 / J Clin Invest Targeting human melanoma neoantigens by T cell receptor gene therapy M. Leisegang T. Kammertoens W. Uckert T. Blankenstein 01. April 2015 / Curr Opin Immunol Targeting cancer-specific mutations by T cell receptor gene therapy T. Blankenstein M. Leisegang W. Uckert H. Schreiber 01. April 2015 / Nat Biotechnol Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice M. Obenaus C. Leitão M. Leisegang X. Chen I. Gavvovidis P. van der Bruggen W. Uckert D.J. Schendel T. Blankenstein 01. August 2022 / Cytotherapy Rapid single-cell identification of Epstein-Barr virus-specific T-cell receptors for cellular therapy M.F. Lammoglia Cobo C. Welters L. Rosenberger M. Leisegang K. Dietze C. Pircher L. Penter R. Gary L. Bullinger A. Takvorian A. Moosmann K. Dornmair T. Blankenstein T. Kammertöns A. Gerbitz L. Hansmann 01. März 2010 / Hum Gene Ther Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma A. Buchner H. Pohla G. Willimsky B. Frankenberger R. Frank A. Baur-Melnyk M. Siebels C.G. Stief A. Hofstetter J. Kopp A. Pezzutto T. Blankenstein R. Oberneder D.J. Schendel 28. Juli 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein 01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto 07. Februar 2020 / EMBO Mol Med "Designer cytokines" targeting the tumor vasculature - think global and act local T. Kammertoens J. Kemna M. Leisegang 15. April 2015 / Int J Cancer Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: tumor-induced immunosuppression and a possible role for NF-κB A. Flörcken M. Grau A. Wolf A. Weilemann J. Kopp B. Dörken T. Blankenstein A. Pezzutto P. Lenz G. Lenz J. Westermann Seitennummerierung Aktuelle Seite 1 Seite 2 Nächste Seite Next › Letzte Seite Last »
08. Februar 2013 / Mol Med High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination H. Pohla A. Buchner B. Stadlbauer B. Frankenberger S. Stevanovic S. Walter R. Frank T. Schwachula S. Olek J. Kopp G. Willimsky C.G. Stief A. Hofstetter A. Pezzutto T. Blankenstein R. Oberneder D.J. Schendel
01. März 2016 / J Clin Invest Targeting human melanoma neoantigens by T cell receptor gene therapy M. Leisegang T. Kammertoens W. Uckert T. Blankenstein
01. April 2015 / Curr Opin Immunol Targeting cancer-specific mutations by T cell receptor gene therapy T. Blankenstein M. Leisegang W. Uckert H. Schreiber
01. April 2015 / Nat Biotechnol Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice M. Obenaus C. Leitão M. Leisegang X. Chen I. Gavvovidis P. van der Bruggen W. Uckert D.J. Schendel T. Blankenstein
01. August 2022 / Cytotherapy Rapid single-cell identification of Epstein-Barr virus-specific T-cell receptors for cellular therapy M.F. Lammoglia Cobo C. Welters L. Rosenberger M. Leisegang K. Dietze C. Pircher L. Penter R. Gary L. Bullinger A. Takvorian A. Moosmann K. Dornmair T. Blankenstein T. Kammertöns A. Gerbitz L. Hansmann
01. März 2010 / Hum Gene Ther Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma A. Buchner H. Pohla G. Willimsky B. Frankenberger R. Frank A. Baur-Melnyk M. Siebels C.G. Stief A. Hofstetter J. Kopp A. Pezzutto T. Blankenstein R. Oberneder D.J. Schendel
28. Juli 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein
01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto
07. Februar 2020 / EMBO Mol Med "Designer cytokines" targeting the tumor vasculature - think global and act local T. Kammertoens J. Kemna M. Leisegang
15. April 2015 / Int J Cancer Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: tumor-induced immunosuppression and a possible role for NF-κB A. Flörcken M. Grau A. Wolf A. Weilemann J. Kopp B. Dörken T. Blankenstein A. Pezzutto P. Lenz G. Lenz J. Westermann